309 related articles for article (PubMed ID: 23027417)
1. Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor.
Olincy A; Freedman R
Handb Exp Pharmacol; 2012; (213):211-32. PubMed ID: 23027417
[TBL] [Abstract][Full Text] [Related]
2. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.
Martin LF; Kem WR; Freedman R
Psychopharmacology (Berl); 2004 Jun; 174(1):54-64. PubMed ID: 15205879
[TBL] [Abstract][Full Text] [Related]
3. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia.
Tregellas JR; Tanabe J; Rojas DC; Shatti S; Olincy A; Johnson L; Martin LF; Soti F; Kem WR; Leonard S; Freedman R
Biol Psychiatry; 2011 Jan; 69(1):7-11. PubMed ID: 20728875
[TBL] [Abstract][Full Text] [Related]
4. α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia.
Freedman R
Annu Rev Med; 2014; 65():245-61. PubMed ID: 24111888
[TBL] [Abstract][Full Text] [Related]
5. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
[TBL] [Abstract][Full Text] [Related]
6. Nicotinic agonists and psychosis.
Simosky JK; Stevens KE; Freedman R
Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):149-62. PubMed ID: 12769624
[TBL] [Abstract][Full Text] [Related]
7. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21).
Kem WR
Behav Brain Res; 2000 Aug; 113(1-2):169-81. PubMed ID: 10942043
[TBL] [Abstract][Full Text] [Related]
8. Initial phase 2 trial of a nicotinic agonist in schizophrenia.
Freedman R; Olincy A; Buchanan RW; Harris JG; Gold JM; Johnson L; Allensworth D; Guzman-Bonilla A; Clement B; Ball MP; Kutnick J; Pender V; Martin LF; Stevens KE; Wagner BD; Zerbe GO; Soti F; Kem WR
Am J Psychiatry; 2008 Aug; 165(8):1040-7. PubMed ID: 18381905
[TBL] [Abstract][Full Text] [Related]
9. Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
Olincy A; Stevens KE
Biochem Pharmacol; 2007 Oct; 74(8):1192-201. PubMed ID: 17714692
[TBL] [Abstract][Full Text] [Related]
10. Activation and desensitization of nicotinic alpha7-type acetylcholine receptors by benzylidene anabaseines and nicotine.
Papke RL; Kem WR; Soti F; López-Hernández GY; Horenstein NA
J Pharmacol Exp Ther; 2009 May; 329(2):791-807. PubMed ID: 19223664
[TBL] [Abstract][Full Text] [Related]
11. Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats.
Callahan PM; Terry AV; Tehim A
Psychopharmacology (Berl); 2014 Sep; 231(18):3695-706. PubMed ID: 24595504
[TBL] [Abstract][Full Text] [Related]
12. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.
Hong LE; Thaker GK; McMahon RP; Summerfelt A; Rachbeisel J; Fuller RL; Wonodi I; Buchanan RW; Myers C; Heishman SJ; Yang J; Nye A
Arch Gen Psychiatry; 2011 Dec; 68(12):1195-206. PubMed ID: 21810630
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of human alpha7 nicotinic receptors by chronic treatment with activator and antagonist ligands.
Molinari EJ; Delbono O; Messi ML; Renganathan M; Arneric SP; Sullivan JP; Gopalakrishnan M
Eur J Pharmacol; 1998 Apr; 347(1):131-9. PubMed ID: 9650859
[TBL] [Abstract][Full Text] [Related]
14. Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice.
Stevens KE; Kem WR; Mahnir VM; Freedman R
Psychopharmacology (Berl); 1998 Apr; 136(4):320-7. PubMed ID: 9600576
[TBL] [Abstract][Full Text] [Related]
15. Diverse strategies targeting α7 homomeric and α6β2* heteromeric nicotinic acetylcholine receptors for smoking cessation.
Brunzell DH; McIntosh JM; Papke RL
Ann N Y Acad Sci; 2014 Oct; 1327(1):27-45. PubMed ID: 24730978
[TBL] [Abstract][Full Text] [Related]
16. Initial Cross-Over Test of A Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers With Or Without Schizophrenia.
Perkins KA; Roy Chengappa KN; Karelitz JL; Boldry MC; Michael V; Herb T; Gannon J; Brar J; Ford L; Rassnick S; Brunzell DH
Neuropsychopharmacology; 2018 May; 43(6):1334-1342. PubMed ID: 29185480
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation.
Kem WR; Olincy A; Johnson L; Harris J; Wagner BD; Buchanan RW; Christians U; Freedman R
Neuropsychopharmacology; 2018 Feb; 43(3):583-589. PubMed ID: 28825423
[TBL] [Abstract][Full Text] [Related]
18. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
Hauser TA; Kucinski A; Jordan KG; Gatto GJ; Wersinger SR; Hesse RA; Stachowiak EK; Stachowiak MK; Papke RL; Lippiello PM; Bencherif M
Biochem Pharmacol; 2009 Oct; 78(7):803-12. PubMed ID: 19482012
[TBL] [Abstract][Full Text] [Related]
19. Effects of α7 nicotinic acetylcholine receptor agonists on antipsychotic efficacy in a preclinical mouse model of psychosis.
Kohlhaas KL; Bitner RS; Gopalakrishnan M; Rueter LE
Psychopharmacology (Berl); 2012 Apr; 220(4):823-33. PubMed ID: 22038534
[TBL] [Abstract][Full Text] [Related]
20. Nicotine blocks apomorphine-induced disruption of prepulse inhibition of the acoustic startle in rats: possible involvement of central nicotinic alpha7 receptors.
Suemaru K; Yasuda K; Umeda K; Araki H; Shibata K; Choshi T; Hibino S; Gomita Y
Br J Pharmacol; 2004 Jul; 142(5):843-50. PubMed ID: 15197106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
